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Early Infections in Kidney Transplant Recipients Under FK 506 
S. Kusne. M. Martin. R. Shapiro, M. Jordan. J. Fung, M. Alessiani, A. Jain. S. Todo, and T. Starzl 
I NFECTION remains a major cause of morbidity and 
mortality in transplant recipients. Sixty-six consecu-
tive kidney transplants in 65 recipients were performed 
between September 1989 and June 3. 1990 using the 
experimental immunosuppressive agent FK 506. This re-
port highlights the early infectious complications. The 
aims of this study were to determine the frequency of early 
infections in kidney recipients under FK 506. and to 
compare infections occurring in patients receiving a first 
renal allograft (primary) with those undergoing kidney 
retransplantation (secondary) using this new agent. 
METHODS 
Forty-one primary and 22 secondary retransplantation patients 
were followed prospectively. Three patients were excluded from 
evaluation due to cardiac death at48 hours and arterial thrombosis 
and allograft loss at 24 hours. and one secondary patient who had 
received intense immunosuppression until the time of his retrans-
plant was also excluded. lOne patient is included in both primary 
and secondary retransplantation groups having been a failure from 
the primary series at 130 days. 
Surveillance cultures were obtained in most patients. In eight 
cases of allograft loss. follow-up was terminated 7 days after 
nephrectomy. Routine prophylaxis included t g cefazolin IV 
every 8 hours for a total of three doses. Bactrim (80 mg trimeth-
oprim/400 mg sulfamethoxazolel daily. 500 000 U oral mycostatin 
three times a day. and high dose acyclovir (800 mg four times a 
day) with doses adjusted according to renal function. 
The immunosuppression protocol included FK 506 and steroids 
in all pattents. A first I V dose of FK 506 at 0.15 mg/kg was given. 
usually in the recovery room. and an IV dose of 0.075 mg/kg dose 
was repeated every 12 hours until oral intake was resumed. Oral 
doses (0.15 mg/kgl were administered twice a day and these were 
increased when indicated by suspected rejection or reduced if 
drug toxicity was seen. Reduced doses were sometimes given 
once a day instead of every 12 hours. The first 25 patients received 
I g IV bolus of methylprednisolone intraoperatively. Prednisone 
was started at 200 mg on the first postoperative day and reduced 
in daily 40 mg steps to a maintenance dose of 20 mg by day 6. The 
remaining patients received low dose (20 mg/d) prednisone from 
the time of surgery. When possible. the steroid dose was tapered 
over the first several weeks and stopped. Supplementary steroids 
Table 1. Characteristics of Those Patients Undergoing Primary 
and Secondary Retranaplantatlon under FK 506 
Patients 
Male/female 
Mean age (y) 
Range 
Diabetes 
Mean follow-up (d) 
Primary 
41 
16125 
42: 14.5 
10-72 
13 
158: 78.6 
Secondary 
22 
17/5 
36: 10.3 
18-63 
5 
147: 90.9 
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TIm. After Tr.nlpllntltlon In Monthl 
FIg 1. Incidence in episodes of infection per patients per year 
and time after kidney transplantation when infections occurred. 
or OKn were given if persistent rejection was suspected clini-
cally or diagnosed with biopsyK~ 
The diagnosis of infection was made using clinical and labora-
tory criteria as previously described. ,I 
Proportions were analyzed with chi-square test and means were 
compared with Student's t test. 
RESULTS 
The study population is shown in Table I and included 41 
primary and 22 secondary retransplantation patients. Dia-
betic nephropathy was the original diagnosis in 18 evalu-
able patients. Mean follow-up time was 152 days with 35 
patients followed for more than 4 months. All infections 
occurred within 4 months with 81 % seen within the first 60 
days (Fig I). No patient died from infection and no 
significant differences were seen in diabetics. The inci-
dence of infections is shown in Table 2. These patients are 
compared with a group of 64 cyclosporine (CyA) patients 
reported from our institution in 1983. 2 Overall. 33% of FK 
506 patients developed infection compared with 61 % of the 
historical CyA patients. Twenty-six episodes of infection 
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INFECTIONS IN TRANSPLANT PATIENTS 
Table 2. Comparison of Infections Between CyA·Treated 
Patients In 1981·1982 (n = 64) and the FK 506 Patients. 
1989-1990 (n = 63) 
CyA FK 506 
All infections 
Patients infected 61% 33% 
Total episodes 63 26 
Mean episodes 0.98 0.41 
Nonviral infections 
Patients infected 41% 21% 
Total episodes 39 16 
Mean episodes 0.61 0.25 
I nfaction related 
Deathsltotal deaths 0/1 DID 
were seen in 21 of 63 study patients. Lethal systemic sepsis 
was notably absent. Of 15 bacterial infections. 8 (53%) 
originated in the urinary tract and were mild. with bacte-
remia (Escherichia coli) accompanying three episodes of 
pyelonephritis. Peritonitis following cecal perforation oc-
curred in one patient who developed colonic pseudo-
obstruction. Superficial wound infections1 and four cases 
of Candida difficile colitis caused the remaining infections. 
The only infection·related graft loss was from a mycotic 
pseudoaneurysm of the iliac anerial anastomosis following 
transmission of candida from an infected allograft. Of 10 
viral infections. 8 were caused by cytomegalovirus (CMY) 
(gastritis. 7: viral syndrome. I). The others included recur-
rent genital herpes and reactivation of Epstein-Barr virus 
mBY) in a patient who presented with diffuse lymphade-
nopathy. Not unexpectedly. three seronegative patients 
receiving allografts from seropositive donors developed 
symptomatic CMY disease (3 of9 or 33%). In comparison. 
no CMY was documented in 20 seronegative recipients 
receiving seronegative grafts (P < .0 I). The rate of symp-
tomatic CMY in seropositive recipients was 15% or 5 of 34 
patients. Patients undergoing secondary transplantation 
had a similar distribution but higher bacterial and overall 
rates of infection when compared with primary recipients 
(0.68 episodes per patient vs 0.27 episodes per patient. P < 
.05. Table 2). 
957 
DISCUSSION 
Infections remain an imponant cause of morbidity after 
kidney transplantation and can be influenced by both 
technical factors and the need for immunosuppression. 
Following the introduction of Cy A in 1981. we reponed a 
comparison of infections between this "new" agent and 
the standard azathioprine therapy and found a lower rate 
of serious infections. 3 Since its introduction in 1989. our 
enthusiasm for FK 506 only increases as its powerful 
immunosuppressive ability does not appear to increase the 
infectious risk. No death in this series was related to 
infection nor did diabetic patients appear at increased risk. 
Our approach to prophylaxis has changed over the last 2 
years. All patients receive Bactrim and none have devel-
oped Pneumocystis carini; pneumonia. Two patients (3%) 
developed non-CMY viral infections in the FK 506 group 
and when compared with the early repon of 16 patients 
(25%) this impressive reduction in symptomatic herpes 
infection may be due to the introduction of acyclovir 
prophylaxis prior to the FK 506 trial. Donor transmission 
of candida resulted in the only allograft loss due to 
infection. 
The higher infections seen in the secondary group are 
likely due to the longer duration of immunosuppression. 
Interpretation of these observations must be met with 
caution as changes in management and prophylaxis have 
occurred since our early repon on CyA-treated patients. 
As well. follow-up has been less than II months overall. 
The ability to decrease steroid usage. while maintaining 
adequate single agent immunosuppression. suggests that 
FK 506 may be a superior drug and this may be an 
imponant factor in the relative freedom from serious 
infections. 
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